1. Home
  2. ATOM vs ZNTL Comparison

ATOM vs ZNTL Comparison

Compare ATOM & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Atomera Incorporated

ATOM

Atomera Incorporated

HOLD

Current Price

$8.20

Market Cap

283.0M

Sector

Technology

ML Signal

HOLD

Logo Zentalis Pharmaceuticals Inc.

ZNTL

Zentalis Pharmaceuticals Inc.

HOLD

Current Price

$4.35

Market Cap

289.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATOM
ZNTL
Founded
2001
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
283.0M
289.0M
IPO Year
2016
2020

Fundamental Metrics

Financial Performance
Metric
ATOM
ZNTL
Price
$8.20
$4.35
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$6.60
AVG Volume (30 Days)
1.1M
1.3M
Earning Date
05-05-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
4.41
18.03
EPS
N/A
N/A
Revenue
$62,000.00
N/A
Revenue This Year
$527.69
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.89
$1.15
52 Week High
$12.37
$6.95

Technical Indicators

Market Signals
Indicator
ATOM
ZNTL
Relative Strength Index (RSI) 49.04 57.50
Support Level $7.23 $3.53
Resistance Level $10.06 $6.95
Average True Range (ATR) 0.80 0.37
MACD -0.06 0.11
Stochastic Oscillator 48.25 53.52

Price Performance

Historical Comparison
ATOM
ZNTL

About ATOM Atomera Incorporated

Atomera Inc is engaged in the business of developing, commercializing, and licensing proprietary processes and technologies for the semiconductor industry. The company's technology, named Mears Silicon Technology, or MST, is a thin film of re-engineered silicon, typically 100 to 300 angstroms (or approximately 20 to 60 silicon atomic unit cells) thick. MST can be applied as a transistor channel enhancement to CMOS-type transistors, the majority of widely used in the semiconductor industry. The company's silicon technology can be used for applications like Analog, DRAM, logic, processors, and SRAM. Geographically, it generates maximum revenue from North America.

About ZNTL Zentalis Pharmaceuticals Inc.

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Share on Social Networks: